Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026 Enrollment ongoing in CREAATE, a pivotal study of
People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-being Study results informed the design and endpoint selection of the ongoing Phase 3 CREAATE study ZUG, Switzerland, Aug.
Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile PDUFA
Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentation Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented ZUG, Switzerland,
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema
